Should I buy or sell Pacira BioSciences stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PCRX shares. View PCRX analyst ratings or view top-rated stocks .

What is Pacira BioSciences' stock price target for 2024?

10 brokers have issued 1-year target prices for Pacira BioSciences' stock. Their PCRX share price targets range from $42.00 to $57.00. On average, they expect the company's share price to reach $49.50 in the next twelve months. This suggests a possible upside of 88.9% from the stock's current price. View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts .

How have PCRX shares performed in 2024?

Pacira BioSciences' stock was trading at $33.74 on January 1st, 2024. Since then, PCRX stock has decreased by 22.3% and is now trading at $26.20. View the best growth stocks for 2024 here .

When is Pacira BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our PCRX earnings forecast .

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings data on Thursday, February, 29th. The company reported $0.71 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.71. The business earned $181.24 million during the quarter, compared to the consensus estimate of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a trailing twelve-month return on equity of 12.81%.

What ETFs hold Pacira BioSciences' stock?

ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP) , SPDR S&P Pharmaceuticals ETF (XPH) , Invesco S&P SmallCap Health Care ETF (PSCH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . iShares U.S. Pharmaceuticals ETF (IHE) .

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $680.0 million-$705.0 million, compared to the consensus revenue estimate of $722.5 million.

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com . Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD) , NVIDIA (NVDA) , Micron Technology (MU) , ACADIA Pharmaceuticals (ACAD) , Skyworks Solutions (SWKS) , AbbVie (ABBV) , Pfizer (PFE) , QUALCOMM (QCOM) , Exelixis (EXEL) and Tesla (TSLA) .

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Tributary Capital Management LLC (0.54%), Congress Asset Management Co. MA (0.19%), Bridge City Capital LLC (0.13%), Los Angeles Capital Management LLC (0.05%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Anthony Molloy, Charles A Reinhart III , Charles Anthony Laranjeira, Daryl Gaugler, David M Stack , Donald C Manning , Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams , Lauren Bullaro Riker , Mark A Kronenfeld, Mark Froimson, Max Reinhardt , Paul J Hastings and Roy Winston . View institutional ownership trends .

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:PCRX

Pacira BioSciences (PCRX) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free PCRX Stock Alerts

$26.25

+0.15 (+0.57%)

(As of 04/19/2024 ET)

Compare

Today's Range: $25.91
▼
$26.34
50-Day Range: $26.10
▼
$31.41
52-Week Range: $25.76
▼
$48.60

Volume: 448,972 shs
Average Volume: 497,717 shs
Market Capitalization: $1.22 billion

P/E Ratio: 32.41
Dividend Yield: N/A
Price Target: $49.50

Get Pacira BioSciences alerts:

Pacira BioSciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 88.9% Upside
$49.50 Price Target
Short Interest: Healthy
8.04% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.89
Upright™ Environmental Score
News Sentiment: 0.33
Based on 4 Articles This Week
Insider Trading: Selling Shares
$2.79 M Sold Last Quarter
Proj. Earnings Growth: 29.82%
From $2.18 to $2.83 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.96 out of 5 stars

Medical Sector

14th out of 918 stocks

Pharmaceutical Preparations Industry

6th out of 417 stocks

4.5

Analyst's Opinion

Consensus Rating
Pacira BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Pacira BioSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
8.04% of the outstanding shares of Pacira BioSciences have been sold short.
Short Interest Ratio / Days to Cover
Pacira BioSciences has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Pacira BioSciences has recently decreased by 8.11%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Pacira BioSciences does not currently pay a dividend.
Dividend Growth
Pacira BioSciences does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pacira BioSciences has received a 52.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Bupivacaine", "Cryotherapy devices", and "Drug delivery devices" products. See details.
Environmental Sustainability
The Environmental Impact score for Pacira BioSciences is -1.89.

3.0

News and Social Media Coverage

News Sentiment
Pacira BioSciences has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Pacira BioSciences this week, compared to 3 articles on an average week.
Search Interest
11 people have searched for PCRX on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.
MarketBeat Follows
5 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,785,628.00 in company stock.
Percentage Held by Insiders
Only 6.60% of the stock of Pacira BioSciences is held by insiders.
Percentage Held by Institutions
99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Pacira BioSciences are expected to grow by 29.82% in the coming year, from $2.18 to $2.83 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pacira BioSciences is 32.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.49.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pacira BioSciences is 32.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 207.50.
Price to Book Value per Share Ratio
Pacira BioSciences has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Pacira BioSciences Stock (NASDAQ:PCRX)

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

PCRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PCRX Stock News Headlines

April 19, 2024 | americanbankingnews.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Buy" from Analysts

April 17, 2024 | nasdaq.com

Oversold Conditions For Pacira BioSciences (PCRX)

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 11, 2024 | finance.yahoo.com

Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend

April 10, 2024 | americanbankingnews.com

Pacira BioSciences (NASDAQ:PCRX) Given Buy Rating at Needham & Company LLC

April 9, 2024 | markets.businessinsider.com

Understanding Key Factors Behind Pacira Pharmaceuticals’ Analyst Rating

April 6, 2024 | nasdaq.com

Commit To Purchase Pacira BioSciences At $15, Earn 12.5% Annualized Using Options

April 2, 2024 | globenewswire.com

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 16, 2024 | finance.yahoo.com

PCRX Apr 2024 22.500 put

March 13, 2024 | marketwatch.com

Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis

March 13, 2024 | markets.businessinsider.com

Pacira BioSciences Receives RMAT Designation For Gene Therapy Product Candidate In Osteoarthritis

March 13, 2024 | globenewswire.com

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

March 9, 2024 | finance.yahoo.com

Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX)

March 6, 2024 | globenewswire.com

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

March 4, 2024 | markets.businessinsider.com

Buy Rating for Pacira Pharmaceuticals Amid Strong Growth Prospects and Robust IP Protection

March 3, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Pacira Pharmaceuticals Amid Strategic Growth Initiatives and Management Restructuring

March 1, 2024 | markets.businessinsider.com

Navigating 4 Analyst Ratings For Pacira BioSciences

March 1, 2024 | finance.yahoo.com

Pacira BioSciences Full Year 2023 Earnings: EPS Beats Expectations

March 1, 2024 | finance.yahoo.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript

March 1, 2024 | markets.businessinsider.com

Strong Buy Rating for Pacira Pharmaceuticals Amid Favorable NOPAIN Act Implications and Strategic Growth Initiatives

March 1, 2024 | finance.yahoo.com

Q4 2023 Pacira Biosciences Inc Earnings Call

February 29, 2024 | msn.com

Pacira BioSciences GAAP EPS of $0.54 beats by $0.15, revenue of $181.2M beats by $0.34M

February 29, 2024 | finance.yahoo.com

Pacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023

February 29, 2024 | globenewswire.com

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

February 28, 2024 | benzinga.com

Preview: Pacira BioSciences's Earnings

February 28, 2024 | msn.com

Pacira BioSciences Q4 2023 Earnings Preview

See More Headlines

Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:PCRX
CUSIP: 69512710
CIK: 1396814
Web: www.pacira.com
Phone: (813) 553-6680
Fax: 302-655-5049
Employees: 712
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $49.50
High Stock Price Target: $57.00
Low Stock Price Target: $42.00
Potential Upside/Downside: +90.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.81
Trailing P/E Ratio: 32.11
Forward P/E Ratio: 11.93
P/E Growth: N/A
Net Income: $41.96 million
Net Margins: 6.22%
Pretax Margin: 9.14%
Return on Equity: 12.81%
Return on Assets: 6.80%

Debt

Debt-to-Equity Ratio: 0.59
Current Ratio: 5.24
Quick Ratio: 4.17

Sales & Book Value

Annual Sales: $674.98 million
Price / Sales: 1.79
Cash Flow: $3.85 per share
Price / Cash Flow: 6.76
Book Value: $18.74 per share
Price / Book: 1.39

Miscellaneous

Outstanding Shares: 46,500,000
Free Float: 43,432,000
Market Cap: $1.21 billion
Optionable: Optionable
Beta: 0.76

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Charles A. Reinhart III (Age 63)
CPA, M.B.A., Chief Financial Officer
Comp: $780.58k
Mr. Daryl Gaugler (Age 62)
Chief Operating Officer
Comp: $778.77k
Ms. Kristen Williams J.D. (Age 50)
Chief Administrative Officer & Secretary
Comp: $799.63k
Mr. Anthony Molloy III (Age 50)
Esq., Chief Legal & Compliance Officer
Comp: $581.41k
Mr. David M. Stack (Age 74)
Advisor
Comp: $1.54M
Mr. Frank D. Lee (Age 56)
CEO & Director
Ms. Lauren Bullaro Riker (Age 45)
Principal Accounting Officer & Senior VP of Finance
Comp: $288.81k
Susan Mesco
Head of Investor Relations
Mr. Richard Kahr
Vice President of Human Resources
Mr. Dennis McLoughlin (Age 58)
Chief Customer Officer
Comp: $535.87k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings or view top-rated stocks.
What is Pacira BioSciences' stock price target for 2024?: 10 brokers have issued 1-year target prices for Pacira BioSciences' stock. Their PCRX share price targets range from $42.00 to $57.00. On average, they expect the company's share price to reach $49.50 in the next twelve months. This suggests a possible upside of 88.9% from the stock's current price.
View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts.
How have PCRX shares performed in 2024?: Pacira BioSciences' stock was trading at $33.74 on January 1st, 2024. Since then, PCRX stock has decreased by 22.3% and is now trading at $26.20.
View the best growth stocks for 2024 here.
When is Pacira BioSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our PCRX earnings forecast.
How were Pacira BioSciences' earnings last quarter?: Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings data on Thursday, February, 29th. The company reported $0.71 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.71. The business earned $181.24 million during the quarter, compared to the consensus estimate of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a trailing twelve-month return on equity of 12.81%.
What ETFs hold Pacira BioSciences' stock?: ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What guidance has Pacira BioSciences issued on next quarter's earnings?: Pacira BioSciences issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $680.0 million-$705.0 million, compared to the consensus revenue estimate of $722.5 million.
What is Dave Stack's approval rating as Pacira BioSciences' CEO?: 54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Pacira BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).
Who are Pacira BioSciences' major shareholders?: Pacira BioSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Tributary Capital Management LLC (0.54%), Congress Asset Management Co. MA (0.19%), Bridge City Capital LLC (0.13%), Los Angeles Capital Management LLC (0.05%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends.
How do I buy shares of Pacira BioSciences?: Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pacira BioSciences (PCRX) Stock Price, News & Analysis

Pacira BioSciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Pacira BioSciences Stock (NASDAQ:PCRX)

PCRX Stock Price History

PCRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PCRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™